Cynosure (CYNO) was Reiterated by Maxim Group to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 66 from a previous price target of $60 . Maxim Group advised their investors in a research report released on Jul 27, 2016.
On the company’s financial health, Cynosure reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $110.30 million for the quarter, compared to analysts expectations of $101.31 million. The company’s revenue was up 31.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.
Cynosure closed down -0.09 points or -0.17% at $53.83 with 2,22,558 shares getting traded on Thursday. Post opening the session at $53.56, the shares hit an intraday low of $53.56 and an intraday high of $54.25 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on May 16, 2016, Douglas J Delaney (Executive VP, Sales) sold 12,299 shares at $46.49 per share price. According to the SEC, on May 16, 2016, Michael R Davin (Chairman and CEO) sold 26,271 shares at $46.49 per share price. On Apr 19, 2016, Timothy W Baker (President and CFO) sold 14,008 shares at $45.02 per share price, according to the Form-4 filing with the securities and exchange commission.
Cynosure Inc. develops and markets aesthetic treatment systems that enable plastic surgeons dermatologists and other medical practitioners to perform procedures to remove hair treat vascular and benign pigmented lesions remove multi-colored tattoos revitalize the skin liquefy and remove unwanted fat through laser lipolysis reduce cellulite clear nails infected by toe fungus ablate sweat glands and improve vaginal health. The Company also markets radiofrequency (RF) energy sourced medical devices for precision surgical applications such as facial plastic and general surgery; gynecology; ear nose and throat procedures; ophthalmology; oral and maxillofacial surgery; podiatry and proctology. The Company offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies.